Patent search ap:("ABBOTT LAB") AND inv:"KESTER JEFFREY A" Page 5

41.

发明专利
Aromatic azocyclics with a biphenyl substituent which are angiotensin II receptor antagonists 未知

公开(公告)号：AU647174B2

公开(公告)日：1994-03-17

申请号：AU8374491

申请日：1991-09-09

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , DE BISWANATH , ZYDOWSKY THOMAS M , KERKMAN DANIEL J , DEBERNARDIS JOHN F , ROSENBERG SAUL H , SHIOSAKI KAZUMI , BASHA FATIMA Z , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , HOLLEMAN WILLIAM H

IPC: A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/53 , A61P1/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P27/02 , A61P43/00 , C07D213/64 , C07D213/70 , C07D213/71 , C07D213/72 , C07D213/74 , C07D213/80 , C07D239/26 , C07D239/34 , C07D239/42 , C07D257/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , A61K31/43 , A61K31/535 , A61K31/41

Abstract: Novel pyrimidine, pyridine, pyridazine, pyrazine and triazine compounds are provided of the formula (I). The compounds of the invention are useful for treating hypertension, edema, renal failure, congestive heart failure, psoriasis and glaucoma, and in the prevention and treatment of atherosclerosis or to treat gastrointestinal disorders associated with enhanced contractility and/or motility of intestinal smooth muscle or to treat contractile disorders of the uterus.

42.

发明专利
Endothelin anatagonists 未知

公开(公告)号：AU2008201198A1

公开(公告)日：2008-04-03

申请号：AU2008201198

申请日：2008-03-12

Applicant: ABBOTT LAB

Inventor： SZCZEPANKIEWICZ BRUCE G , WITTENBERGER STEVEN J , JAE HWAN-SOO , BOYD STEVEN A , KESTER JEFFREY A , KING STEVEN A , WINN MARTIN , HENRY KENNETH J , LIU GANG , TASKER ANDREW S , HUTCHINS CHARLES W , SORENSEN BRYAN K , GELDEM THOMAS W VON

IPC: C07D405/00

43.

发明专利
未知

公开(公告)号：DK0885215T3

公开(公告)日：2006-08-14

申请号：DK97905816

申请日：1997-02-12

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , VON GELDERN THOMAS W , SORENSEN BRYAN K , LIU GANG , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , KESTER JEFFREY A , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J JR , WITTENBERGER STEVEN J , KING STEVEN A

IPC: C07D405/04 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572 , C07F9/59

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

44.

发明专利
Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists 未知

公开(公告)号：NZ514170A

公开(公告)日：2005-02-25

申请号：NZ51417097

申请日：1997-02-12

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN SOO , TASKER ANDREW S , VON GELDERN THOMAS V , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A

IPC: A61K31/40 , A61P9/00 , A61P19/00 , C07D207/16 , C07D401/04 , C07D405/04 , C07D405/14 , C07F9/572

Abstract: A process for preparing a compound of formula (I), wherein: E is a carboxy-protecting group and R1 and R2 are loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl,aminocarbonyalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, heterocyclic and (heterocyclic)alkyl Wherein cycloalkyl, aryl and heterocyclic may be optionally substituted, provided at least one of the following conditions apply: (a) R1 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, and (heterocyclic)alkyl, (b) R2 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, (c) at least on of the optionally substituted aryl groups has at least on substituent selected from hydroxyalkyl and cyano or (d) at least one of the optionally substituted heterocyclic groups has at least one substituent selected from alkyloxycarbonyl, nitro and cyano; comprises a) catalytic hydrogenation of a compound of Formula (II) b)catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids, and c) epimerization of the product of step b) with a base. Also described is the compound (2R, 3R, 4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl-aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid. This compound can be used in the manufacture of a medicament for antagonizing endothelin treating hypertension, congestive heart failure, restinosis cerebral or myocardial ischemia or atherosclerosis, treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporine-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardio toxicity nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury raynaud's disease, migraine and for treating bone pain. (62) Divided out of 503365